| |
Relief of Treatment Symptoms
|
test of association (p value)
|
Improve Functional Well-being
|
test of association (p value)
|
---|
| |
(mean scores)
|
All Respondents
| |
0.25
| |
0.30
| |
Percent reporting no net effect
|
26%
| |
37%
| |
Sex
| | | | |
Male
|
0.23
|
t
|
0.25
|
t
|
Female
|
0.27
|
(0.092)
|
0.36
|
(< 0.001)
|
Age group
| | | | |
20 – 49
|
0.30
| |
0.42
| |
50 – 59
|
0.27
|
r = -0.03
|
0.29
|
r = -0.08
|
60 – 69
|
0.23
|
(0.389)
|
0.30
|
(0.016)
|
70 and older
|
0.25
| |
0.26
| |
Cancer group
| | | | |
Lung, stomach, liver
|
0.23
|
F
|
0.28
|
F
|
Colon, breast, uterus, cervix
|
0.29
|
(0.060)
|
0.35
|
(0.004)
|
Prostate, other
|
0.21
| |
0.15
| |
Lung
|
No
|
0.27
|
t
|
0.32
|
t
|
|
Yes
|
0.20
|
(0.032)
|
0.26
|
(0.190)
|
Stomach
|
No
|
0.25
|
t
|
0.29
|
t
|
|
Yes
|
0.27
|
(0.379)
|
0.34
|
(0.245)
|
Liver
|
No
|
0.26
|
t
|
0.31
|
t
|
|
Yes
|
0.18
|
(0.026)
|
0.23
|
(0.059)
|
Colon
|
No
|
0.24
|
t
|
0.29
|
t
|
|
Yes
|
0.29
|
(0.074)
|
0.33
|
(0.295)
|
Breast
|
No
|
0.25
|
t
|
0.29
|
t
|
|
Yes
|
0.26
|
(0.725)
|
0.36
|
(0.192)
|
Uterus
|
No
|
0.25
|
t
|
0.29
|
t
|
|
Yes
|
0.39
|
(0.075)
|
0.50
|
(0.051)
|
Cervix
|
No
|
0.25
|
t
|
0.30
|
t
|
|
Yes
|
0.26
|
(0.836)
|
0.42
|
(0.159)
|
Prostate
|
No
|
0.25
|
t
|
0.32
|
t
|
|
Yes
|
0.21
|
(0.277)
|
0.14
|
(0.002)
|
History using sen-sei-ro
| | | | |
≤ 3 months
|
0.14*
| |
0.22
| |
3 – 6 months
|
0.24
|
r(s) = 0.07
|
0.30
|
r(s) = 0.04
|
6 – 12 months
|
0.25
|
(0.059)
|
0.29
|
(0.251)
|
> 12 months
|
0.27
| |
0.32
| |
Current treatment
| | | | |
No active treatment
|
0.24
|
F
|
0.31
|
F
|
Oral or radiation therapy
|
0.26
|
0.640
|
0.30
|
0.973
|
Intravenous chemotherapy
|
0.26
| |
0.30
| |
- t: t-test.
- F: F, analysis of variance.
- r: Pearson correlation coefficient; r(s): Spearman correlation coefficient.
- * Group mean is significantly (p < 0.05) lower than means for other groups, which are not significantly different from one another